Introduction
The formation of new blood vessels within the tumor microenvironment, a process known as tumor angiogenesis, promotes tumor growth and metastatic spreading (1, 2) . Although newly formed tumor vessels originate mostly by sprouting angiogenesis from locally preexisting vessels, increasing evidence indicates that tumor-mobilized bone marrow-derived (BMD) cells significantly contribute to tumor angiogenesis. Two mechanisms have been reported. On the one side, tumors mobilize endothelial progenitors capable of differentiating into mature endothelial cells and incorporating into the nascent tumor endothelium (3) . On the other side, tumors mobilize myeloid cells, which accumulate in the tumor microenvironment and promote tumor angiogenesis through paracrine mechanisms (4, 5) . A number of elegant studies combining cell surface phenotyping, in vivo cell tracing, and functional experiments identified multiple angiogenesis-promoting CD11b þ BMD cell populations in mice and human (6) (7) (8) (9) (10) (11) . Little is known, however, on the mechanisms by which tumor-mobilized CD11b þ myeloid cells are programmed to acquire proangiogenic properties. One proposed mechanism is that programming is induced by the tumor on recruitment to the tumor microenvironment (4) . Alternatively, programming may occur early on during myeloid cell differentiation from hematopoietic progenitors. In this work, we have addressed this second hypothesis through experimental studies in vitro and in vivo and correlative analyses in cancer patients.
Materials and Methods

Proteins and chemicals
Human recombinant placenta growth factor (PlGF) was kindly provided by Prof. Kurt Ballmer, Paul Scherrer Institute, Villigen, Switzerland. Human VEGFA, VEGFB, interleukin (IL) 8, and IL1b and mouse FGF (fibroblast growth factor) were purchased from PeproTech EC Ltd. Human stem cell factor (SCF), Flt-3, IL6, and TPO (thrombopoietin) were purchased from R&D Systems. 4
0 ,6-Diamidino-2-phenylindole, dihydrochloride (DAPI) was purchased from LuBioscience GmbH. Ficoll Histopaque Plus 1.077 were from Sigma-Aldrich Chemistry.
Antibodies
Anti-human antibodies. Fluorescein isothiocyanate (FITC)-conjugated anti-CD11b, anti-CD14, anti-Ki67; phycoerythrin (PE)-conjugated anti-CD14, PerCP-conjugated anti-CD34; allophycocyanin (APC)-conjugated anti-CD11b; and Pacific Blue-conjugated anti-CD45 were purchased from BD Pharmingen (Becton Dickinson). PE-conjugated anti-Flt-1, APC-conjugated anti-Flt-1, and IgG1 isotype control were purchased from R&D Systems. The function-blocking antihuman Flt-1 antibody KM1732 was described before (12) .
Anti-mouse antibodies. FITC-conjugated anti-CD11b and APC-conjugated anti-CD45 were purchased from BD Pharmingen (Becton Dickinson). Unconjugated anti-F4/80 and anti-CD31, PerCP-conjugated anti-F4/80, and PerCP-conjugated rat anti-IgG2a isotype control were purchased from Biolegend.
Cell lines and primary cells
The human breast cancer cell line MDA-MB-231 and human nontransformed breast epithelium-derived cell line MCF10A were purchased from American Type Culture Collection (HTB-26D and CRL-10317) and cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin (P/S; Invitrogen). The primary human mammary epithelial cell (HMEC) line, isolated from normal human breast tissue obtained from reduction mammoplasties and the tumorigenic Wnt-1-transformed HMEC line (Wnt-1-HMEC) were provided by Dr. C. Brisken, ISREC-EPFL (13) . Cell-conditioned medium (CCM; 2-4 days old) was collected from cell lines at near-confluence conditions, filtered at 0.2 mm, and stored at À20 C. The mouse breast cancer cell line 4T1 was provided in 2008 by Dr. Fred R. Miller (Michigan Cancer Foundation, Detroit, MI), who originally generated them (14) . We have not tested/authenticated these cell lines after reception in our laboratory. 4T1 cells were cultured in DMEM (Dulbecco's modified Eagle' medium) high glucose supplemented with 10% FCS and 1% P/S. Human umbilical vein endothelial cells (HUVEC) were prepared and cultured as described previously (15) In vitro angiogenesis sprouting assay HUVEC or MLEC cells were trypsinized and cultured during 24 hours in U-bottom 96-well plates to form spheroids (17) Spheroids were collected and transferred to 1% collagen. Cells or cytokines to be tested for angiogenic sprouting activity were added on top of the gel. After 48 (HUVEC) or 24 (MLEC) hours, sprouting was scored by measuring the length of the sprouts using Axiovision Software (Zeiss). Data are presented as mean of cumulated sprout lengths from 10 spheroids AE SD.
Cytokine measurement
Measurements of human or mouse PlGF were conducted in duplicate using the Quantikine ELISA systems (R&D Systems). Results represent means of duplicate determinations AE SD.
Tumor model
4T1 cells were injected (5 Â 10 4 cells in 50 mL PBS/20% Matrigel per injection, respectively) in the fourth right inguinal mammary gland of 4-to 6-week-old BALB/c female mice (Harlan or Charles River Laboratories). Tumor growth was measured twice a week with a caliper and tumor volume was calculated with the equation: volume ¼ p/6 (length Â width 2 ).
Single-cell suspensions from tumors were obtained as recently reported (18) . Mouse experiments were approved by the cantonal veterinary service of Canton Vaud.
Tumor perfusion measurement by power Doppler Measurements were conducted 21 days after tumor cell line injection using the VEVO 770 Micro Three-dimensional HighFrequency Doppler Ultrasound system (VisualSonics) equipped with a 30 MHz transducer. Mice were anesthetized by inhaling a mixture of isoflurane (1.5%) and oxygen (98.5%). The anesthetized animals were placed on a warmed examination table, and the tumors were covered with ultrasound gel. An ultrasound transducer mounted on a 3-dimensional (3D) motor on a rail system above the animal, moved perpendicular to the beam axis, thereby acquiring consecutive 2-dimensional images in B mode and power Doppler mode with a slice thickness/interval of 500 mm. A region of interest (ROI) was drawn within every 2D image. Two-dimensional ultrasound images were used to compile a 3D volume using VisualSonic software. Intratumoral perfusion was determined by measuring the Doppler-derived pixels over a constant surface placed over the most perfused area of each of 3 sections per tumor using ImageJ free software (http://rsbweb.nih.gov/ij/). Five to 7 tumors per each experimental condition were measured (4T1 wild type, 4T1 nonsilenced, and 4T1 sh-PlGF).
Corneal angiogenesis assay
Corneal angiogenesis assay was conducted on the basis of a modification of the method originally reported (19) . CD11b þ cells purified by immunomagnetic beads (StemCell Technologies Inc.) were resuspended at 20 Â 10 6 cells/mL in RPMI 1640 medium with 2% FCS. NOD/SCID (severe combined immunodeficient)/IL2 receptor common g2 chain knockout mice were anesthetized with ketamine and xylazine and 5 mL of cell aliquots were injected into the corneas using a 35-gauge NanoFil injection kit (WPI). Eyes' vascularization was monitored with a stereomicroscope and mice were euthanized 20 days postinjection.
Breast cancer patients and healthy donors
Peripheral blood from healthy donors and cancer patients was obtained according to the declaration of Helsinki and on approval by the ethic committee of the University Hospital and University of Lausanne. Breast cancer patients aged from 32 to 75 years (mean: 56.7 AE 13.4) were all previously untreated and presenting at first diagnosis with ductal invasive carcinoma without evidence of distant metastasis (T1 and T2, N0 and N1, M0), estrogen receptor (ER) positive (85%-95%), and scheduled for tumor resection (10 patients). Blood was collected the day before surgery. Healthy volunteers were individuals without history of cancer, chronic disease, or medication other than hormonal contraception. PBMCs were isolated using Ficoll Histopaque Plus 1.077 (Becton Dickinson).
Human samples processing
Blood was collected in Lithium heparin anti-coagulated Vacutainer tubes (Becton Dickinson). Plasma phase was collected and centrifuged 5 minutes at 1,500 Â g at room temperature. Plasma was stored at À80 C. PBMC were isolated using Ficoll Histopaque Plus 1.077 (25 minutes centrifugation at 680 Â g at room temperature). The PBMC fraction was collected, washed in PBS, counted, aliquoted at 10 Â 10 6 cells/mL, and frozen at À80 C in 90%FCS/10%DMSO (dimethyl sulfoxide) medium. Twenty-four hours later, samples are transferred into liquid nitrogen.
Statistical analysis
In all experiments of this study, values are expressed as mean AE 95% CI. Statistical analyses were conducted by paired Student's t test unless indicated otherwise. Differences were considered statistically significant at P < 0.05.
Results
Breast cancer CCM induces the generation of proangiogenic CD11b
þ myelomonocytic in CD34 Fig. S1B and C). CD11b þ cells isolated from 7-day-old cultures expanded in the presence of MDA-MB-231-derived CCM-induced robust sprouting in an in vitro endothelial cell-sprouting assay (17) , whereas CD11b þ cells isolated from cultures expanded in BHM alone or BHM supplemented with MCF10A-CCM did not (Fig. 1A) . In a second experiment, CD11b þ generated from CD34 þ -initiated cultures exposed to CCM derived from normal primary HMECs did not induce sprouting, whereas those exposed to CCM derived from the tumorigenic Wnt-1-transformed HMEC line (Wnt-1-HMEC; ref. 13 ) did (Fig. 1B) . These results show that human breast cancer cell lines confer sprouting-promoting activity to CD11b þ myelomonocytic cells generated from CD34 þ progenitor-initiated cultures.
PlGF programs proangiogenic activity in CD11b þ myelomonocytic cells derived from CD34 þ progenitorinitiated cells cultures Several tumor-derived cytokines associated with BMD cell mobilization and angiogenesis were expressed in MDA-MB-231 cells (data not shown). Among these, we tested 5 for their ability to confer proangiogenic properties to CD11b þ cells:
VEGFA, VEGFB, IL8, IL1b, and PlGF. Only CD11b þ cells derived from CD34 þ -initiated cultures supplemented with PlGF induced endothelial sprouting ( Fig. 2A ). This effect was not due to a direct effect of PlGF possibly carried over to the sprouting assay, as PlGF, in contrast to VEGF, did not induce endothelial sprouting even at the highest concentration tested (100 ng/mL; Supplementary Fig. S2A ). PlGF levels were significantly elevated in CCM of Wnt-1-HMEC and MDA-MB-231 cell lines compared with MCF10A and HMEC CCM (Supplementary Fig S2B) . Addition of the function-blocking anti-Flt-1 mAb KM1732 (20) and an Flt-1 trap (sFlt-1-Fc) to CD34 þ cellinitiated cultures exposed to MDA-MB-231-derived CCM or PlGF prevented the generation of CD11b þ cells with sprouting-inducing capacity ( Fig. 2B and Supplementary Fig. S2C ). CD11b þ cells derived from PlGF and MDA-MB-231 CCMstimulated cultures induced a robust angiogenic response in vivo in the mouse corneal angiogenesis assay, whereas CD11b þ cells derived form BHM cultures did not (Fig. 2C) .
Addition of PlGF a later time points in CD34 þ cell-initiated cultures resulted in a progressive decline in the endothelial sprouting activity of generated CD11b þ cells ( Supplementary   Fig. S3 ). In CD34 þ cell-initiated cultures, Flt-1 was expressed on a minority of CD34
, whereas the majority of CD11b þ cells were negative ( Supplementary Fig. S4 ). Differ-
BHM culture and further cultured in the presence of PlGF did not acquire proangiogenic activity (Fig. 2D) . duals, induced endothelial sprouting in vitro (Fig. 3A) . In the same cohort of patients, we observed significantly increased levels of PlGF compared with healthy individuals (Fig. 3B) . Exposure of mature CD11b þ myeloid cells isolated from healthy donors to PlGF, however, did not result in proangiogenic programming, whereas they did after 1-week culture in presence of MDA-MB-231 CCM (Supplementary Fig. S5A ). Sprouting activity was observed in whole CD11b Fig. S6B ). Silencing of PlGF significantly lowered plasma PlGF levels in 4T1 tumor-bearing mice (Fig. 4A ) and slowed tumor growth compared with wild-type 4T1 cells or 4T1 cells transduced with the nonsilencing shRNA as measured by tumor volume (Fig. 4B) or weight (Supplementary Fig. S7 ). The frequency of circulating CD11b þ myelomonocytes in 4T1 tumor-bearing mice was not affected by PlGF silencing (Fig. 2C) . However, circulating CD11b þ cells isolated from mice-bearing PlGF-silenced tumors did not induce sprouting in an in vitro MLEC sprouting assay, compared with CD11b þ cells isolated from control mice bearing wild-type or nonsilenced tumors (Fig. 4D) . Importantly, circulating CD11b þ cells isolated from the blood of tumor-free mice did not induce endothelial sprouting ( Supplementary  Fig. S6C ). PlGF silencing profoundly modified the morphology of the tumor vasculature. While in wild-type and nonsilenced 4T1 tumors, the tumor vessels were highly heterogeneous, ranging from larger vessels with well-formed lumen to microvessels without detectable lumen, in PlGF-silenced tumors vessels were uniformly small without detectable lumen (Fig. 5A) . Power Doppler analysis revealed a significant reduction of blood perfusion in PlGF-silenced 4T1 tumors compared with wild-type or nonsilenced tumors (Fig. 5B) . These results are consistent with a reduced maturation and functionality of tumor vessels in mice-bearing PlGF-silenced tumors. PlGF silencing did not affect the fraction of F4/80 growth, decreases the maturation of the tumor vasculature and perfusion. and impinges on the production of proangiogenic cytokines in the tumor microenvironment.
Metalloproteinase activity is required for sprouting induced by PlGF-programmed CD11b þ myelomonocytic cells Next, we searched for factor(s) mediating the endothelial sprouting activity of PlGF-programmed CD11b þ cells.
Endothelial sprouting was still induced when CD11b þ cells and endothelial spheroids were physically separated using a Transwell system, thus implying the involvement of soluble factors ( Supplementary Fig. S9A ). We analyzed the expression of selected candidate genes by real-time RT-PCR in CD34 þ progenitor-initiated cultures. ITGAM mRNA, the transcript encoding for the CD11b protein, was induced in both BHMand PlGF-supplemented cultures. MMP9 mRNA was induced 30-to 40-fold by PlGF, whereas other potentially relevant transcripts (i.e., VEGFA, TGFB-1, SEMA4D, IF44L, ANG1, or PROK2) were either unaffected or only marginally affected by PlGF (Fig. 6A) . Addition of MMI270, a synthetic hydroxomatetype MMP inhibitors, previously shown to inhibit MMP9 and to suppress tumor angiogenesis (22) , during the sprouting assay fully blocked endothelial sprouting induced by PlGFprogrammed CD11b þ cells (Fig. 6B) . Sprouting induced by VEGF was unaffected ( Supplementary Fig. S9B ). The anti-VEGF blocking antibody bevacizumab caused only a minor, statistically nonsignificant reduction of endothelial cell sprouting induced by PlGF-programmed CD11b þ cells (Supplementary Fig. S9C ). Bevacizumab inhibited VEGF-induced endothelial sprouting, as expected ( Supplementary Fig. 9C ).
From these results, we conclude that PlGF induces MMP9 expression during programming of CD11b þ cells and that metalloproteinase activity is required for sprouting activity of PlGF-programmed CD11b þ cells.
Discussion
Different myeloid cell subsets with proangiogenic and tumor-promoting properties have been recently reported Infiltrating CD11b þ cells are F4/80 Two important corollaries stem from these observations. First, endothelial cell sprouting-inducing activity of circulating CD11b þ cells might be a potential biomarker of angiogenesis (25) . Second, circulating CD11b þ monocytes possessing proangiogenic capacity and homing to normal tissues (e.g., lung and bone) might promote metastatic spreading by facilitating initial angiogenesis and thereby contributing to tumor cell extravasation and formation of the premetastatic niche (26, 27) . A translational study aimed at testing these hypotheses is currently in progress in our breast cancer clinic. Cumulating evidence point to a role of PlGF in promoting human cancer progression including breast cancer. PlGF expression is increased in breast cancer tissues compared with normal breast and elevated PlGF levels are associated with elevated risk for recurrence, metastasis, and reduced survival (28, 29) . Elevated levels of PlGF also correlate with progression and reduced survival in mesothelioma (30) , oral (31) , non-small cell lung (32) , colon (33) , renal (34), brain (35) , hepatocellular (36) , and gastric (37) cancers. Genetic ablation of PlGF or antibody-based PlGF inhibition suppressed tumor angiogenesis and tumor growth and enhanced efficacy of anti-VEGF therapy (38) (39) (40) . The angiogenic activity of PlGF appears indirect and mediated by BMD myeloid cells recruited to sites of angiogenesis (39, 41) . Recently, the role of PlGF in promoting tumor angiogenesis has been challenged by a report (42) in which new anti-PlGF antibodies failed to suppress tumor angiogenesis.
By showing that PlGF programs proangiogenic activity in differentiating CD11b þ cells, we provide further evidence for its role in cancer (38, 41) . Furthermore, we identified MMP9 as being strongly upregulated by PlGF and show that MMP inhibition suppresses the proangiogenic activity of programmed CD11b þ cells. MMP9 is thought to promote angiogenesis through the release of matrixbound VEGF at tumor sites (43) and by mobilizing BMD cells (44) . MMP9 is also induced by primary tumors in an Flt-1-dependent manner in endothelial cells and macrophages at premetastatic sites in the lung (45) . Whether MMP9 expression in the lungs was due to a PlGF-mediated angiogenic programming and recruitment of monocytes was not addressed in that study. Thus, our results provide experimental evidence for a functional link between PlGF and MMP9 expression during proangiogenic programming of CD11b þ cells and requirement of MMP activity in promoting endothelial sprouting. Taken together, our work unravels a previously unrecognized activity of PlGF, namely the proangiogenic programming of differentiating CD11b þ myelomonocytic cells, with relevant implications to breast cancer biology, detection, and treatment and reinforces published observations on the contribution of the PlGF/Flt-1 axis in cancer progression.
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